David Magnus, Ph.D.

Publications

• 100th issue anniversary editorial. Magnus D, Am J Bioeth. 2013; 13 (1): 1-2
• Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing. Allyse MA, Sayres LC, Havard M, King JS, Greely HT, Hudgins L, Taylor J, Norton ME, Cho MK, Magnus D, Ormond KE. Prenat Diagn. 2013: 1-6
• Can informed consent go too far? Balancing consent and public benefit in research. Milner LC, Magnus D. Am J Bioeth. 2013; 13 (4): 1-2
• Parental refusal of vaccination and transplantation listing decisions: a nationwide survey. Ladd JM, Karkazis K, Magnus D. Pediatr Transplant. 2013; 17 (3): 244-50
• Risk, consent, and SUPPORT. Magnus D, Caplan AL. N Engl J Med. 2013; 368 (20): 1864-5
• Suicide and the sufficiency of surrogate decision makers. Taye H, Magnus D. Am J Bioeth. 2013; 13 (3): 1-2
• Informational risk, institutional review, and autonomy in the proposed changes to the common rule. Allyse M, Karkazis K, Lee SS, Tobin SL, Greely HT, Cho MK, Magnus D. IRB. 2012 May-Jun; 34 (3): 17-9
• Customers or research participants? Guidance for research practices in commercialization of personal genomics. Tobin SL, Cho MK, Lee SS, Magnus DC, Allyse M, Ormond KE, Garrison NA. Genet Med. 2012; 14 (10): 833-5
• Duty-free: the non-obligatory nature of preimplantation genetic diagnosis. Sayres LC, Magnus D. Am J Bioeth. 2012; 12 (4): 1-2
• The instrumental role of hospital ethics committees in policy work. Garrison NA, Magnus D. Am J Bioeth. 2012; 12 (11): 1-2
• Triggers for research ethics consultation. Havard M, Cho MK, Magnus D. Sci Transl Med. 2012; 4 (118): 118cm1
• Beyond the IRB: local service versus global oversight. Havard M, Magnus D. Am J Bioeth. 2011; 11 (5): 1-2
• Can the dead donor rule be resuscitated? Vernez SL, Magnus D. Am J Bioeth. 2011; 11 (8): 1
• Medical and graduate students' attitudes toward personal genomics. Ormond KE, Hudgins L, Ladd JM, Magnus DM, Greely HT, Cho MK. Genet Med. 2011; 13 (5): 400-8
• Sexless reproduction: a status symbol. Havard M, Magnus D. Am J Bioeth. 2011; 11 (3): 1
• Empirical methods in bioethics: a cautionary tale. Braddock CH, Magnus D. Ann Intern Med. 2010; 152 (6): 396-7
• The history of the American Journal of Bioethics. Magnus D, Am J Bioeth. 2010; 10 (10): 3
• Translating stem cell research: challenges at the research frontier. Magnus D, J Law Med Ethics. 2010; 38 (2): 267-76
• Direct-to-consumer genetic tests: beyond medical regulation? Magnus D, Cho MK, Cook-Deegan R. Genome Med. 2009; 1 (2): 17
• Emergency innovation: implications for the trauma surgeon. Pretz JL, Magnus D, Spain DA. J Trauma. 2009; 67 (6): 1443-7
• Use of neurodevelopmental delay in pediatric solid organ transplant listing decisions: inconsistencies in standards across major pediatric transplant centers. Richards CT, Crawley LM, Magnus D. Pediatr Transplant. 2009; 13 (7): 843-50
• Research ethics consultation: the Stanford experience. Cho MK, Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D. IRB. 2008 Nov-Dec; 30 (6): 1-6
• Response to Open Peer Commentaries on "Strangers at the Beachside: Research Ethics Consultation" Cho MK, Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D. Am J Bioeth. 2008; 8 (3): 4-6
• Strangers at the benchside: research ethics consultation. Cho MK, Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D. Am J Bioeth. 2008; 8 (3): 4-13
• The green revolution in bioethics. Magnus D, Am J Bioeth. 2008; 8 (8): 1-2
• Blood, sweat and tears. Magnus D, Am J Bioeth. 2006 May-Jun; 6 (3): 1-2
• A commentary on oocyte donation for stem cell research in South Korea. Magnus D, Cho MK. Am J Bioeth. 2006 Jan-Feb; 6 (1): W23-4
• Stem cell research: the California experience. Magnus D, Hastings Cent Rep. 2006 Jan-Feb; 36 (1): 26-8
• Research conduct. Lessons of the stem cell scandal. Cho MK, McGee G, Magnus D. Science. 2006; 311 (5761): 614-5
• Ethics. Issues in oocyte donation for stem cell research. Magnus D, Cho MK. Science. 2005; 308 (5729): 1747-8
• Stem cell research should be more than a promise. Magnus D, Hastings Cent Rep. 2004 Sep-Oct; 34 (5): 35-6
• Politics and peer review. Magnus D, Am J Bioeth. 2004; 4 (1): 7-8
• New life forms: new threats, new possibilities. Caplan AL, Magnus D. Hastings Cent Rep. 2003 Nov-Dec; 33 (6): 7
• Evaluating graduate programs in bioethics: what measures should we use? McGee G, Magnus D, Carroll K. Am J Bioeth. 2002; 2 (4): 1-2
• In focus. Core faculty and their publications at bioethics centers in the United States. Magnus D, Miller V, Carroll K. Am J Bioeth. 2002; 2 (4): W20
• Is there a bioethicist in your company? Should there be? Magnus D, Drug Discov Today. 2002; 7 (7): 385-7
• Protecting subjects' interests in genetics research. Merz JF, Magnus D, Cho MK, Caplan AL. Am J Hum Genet. 2002; 70 (4): 965-71
• The meaning of graduate education for bioethics. Magnus D, Am J Bioeth. 2002; 2 (4): 10-2
• Who Owns Life? David Magnus, Ed. with Art Caplan and Glenn McGee. Who Owns Life?. 2002
• Bioethics programs evolve as they grow. Magnus D, Nat Biotechnol. 2001; 19 (10): 991-2
• Family problems. Magnus D, Dagostino L. Am J Bioeth. 2001; 1 (3): 1
• NAS cloning hearing disappoints participants. Magnus D, Caplan A. Science. 2001; 294 (5547): 1651
• Reason and repugnance. Callahan D, Magnus D. Med Ethics (Burlingt Mass). 2001: 6-7
• Ethical issues: from genome to therapy. Magnus D, Novartis Found Symp. 2000: 229 122-5; discussion 125-30
• Policy forum: genetics. Ethical considerations in synthesizing a minimal genome. Cho MK, Magnus D, Caplan AL, McGee D. Science. 1999; 286 (5447): 2087, 2089-90
• What is immoral about eugenics? Caplan AL, McGee G, Magnus D. BMJ. 1999; 319 (7220): 1284-5
• Disease gene patenting: the clinician's dilemma. Magnus D, Camb Q Healthc Ethics. 1998; 7 (4): 433-5